{"id":5975,"date":"2025-06-19T09:35:55","date_gmt":"2025-06-19T09:35:55","guid":{"rendered":"https:\/\/www.enyopharma.com\/fr\/?p=5975"},"modified":"2025-06-19T09:39:44","modified_gmt":"2025-06-19T09:39:44","slug":"alport-connect-2025","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/alport-connect-2025\/","title":{"rendered":"Alport Connect 2025, la rencontre annuelle am\u00e9ricaine avec les patients atteints du syndrome d\u2019Alport"},"content":{"rendered":"

19-20 Juillet 2025
\nChicago, USA<\/p>\n

Âé¶¹ÆÆ½â°æ soutient, cette ann\u00e9e encore, la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2025, organis\u00e9 les 19 et 20 juillet \u00e0 Chicago (USA).
\nÂé¶¹ÆÆ½â°æ rencontrera les patients et leur famille pour leur pr\u00e9senter son \u00e9tude clinique de Phase 2 “ALPESTRIA-1” en cours avec Vonafexor chez les patients atteints du syndrome d’Alport.<\/p>\n

https:\/\/alportsyndrome.org\/for-patients\/alport-connect\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

19-20 Juillet 2025
\nChicago, USA<\/p>\n

Âé¶¹ÆÆ½â°æ soutient, cette ann\u00e9e encore, la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2025, organis\u00e9 les 19 et 20 juillet \u00e0 Chicago (USA).
\nÂé¶¹ÆÆ½â°æ rencontrera les patients et leur famille pour leur pr\u00e9senter son \u00e9tude clinique de Phase 2 “ALPESTRIA-1” en cours avec Vonafexor chez les patients atteints du syndrome d’Alport.<\/p>\n

Lire la suite »<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-5975","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"adm-cdubreuil","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/adm-cdubreuil\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"19-20 Juillet 2025 Chicago, USA Âé¶¹ÆÆ½â°æ soutient, cette ann\u00e9e encore, la fondation am\u00e9ricaine pour les patients atteints du syndrome d’Alport (Alport Syndrome Foundation, ASF) et participera \u00e0 l’\u00e9v\u00e8nement annuel Alport Connect 2025, organis\u00e9 les 19 et 20 juillet \u00e0 Chicago (USA). Âé¶¹ÆÆ½â°æ rencontrera les patients et leur famille pour leur pr\u00e9senter son \u00e9tude…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=5975"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5975\/revisions"}],"predecessor-version":[{"id":5980,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/5975\/revisions\/5980"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=5975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=5975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=5975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}